试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
编号:NCT04172597登记状态:提前终止企业 / 申办者:Spectrum Pharmaceuticals, Inc
药物 / 成分:Poziotinib Hydrochloride、Loperamide
登记的停止原因(原文):Strategic business decision (unrelated to safety)
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
编号:NCT04197986登记状态:提前终止企业 / 申办者:QED Therapeutics, a BridgeBio company
药物 / 成分:Infigratinib、Placebo
登记的停止原因(原文):The sponsor has decided to close the study due to the discontinuation of infigratinib development. The discontinuation of the study was not due to safety reasons.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
Losmapimod Safety and Efficacy in COVID-19
编号:NCT04511819登记状态:提前终止企业 / 申办者:Fulcrum Therapeutics
药物 / 成分:Losmapimod oral tablet、Placebo oral tablet
登记的停止原因(原文):Study terminated due to the rapidly evolving environment for the treatment of Covid-19 and ongoing challenges to identify and enroll qualified patients to participate.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion
编号:NCT04529954登记状态:提前终止企业 / 申办者:Cerebral Therapeutics LLC
药物 / 成分:Valproic Acid delivered to ICV
登记的停止原因(原文):Company Decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases
编号:NCT04610684登记状态:提前终止企业 / 申办者:Jeffrey Clarke
药物 / 成分:Carboplatin、Etoposide、Atezolizumab
登记的停止原因(原文):Lack of Enrollment
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
编号:NCT04612725登记状态:提前终止企业 / 申办者:AstraZeneca
药物 / 成分:Benralizumab、Placebo and Benralizumab
登记的停止原因(原文):Study did not meet primary endpoint
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
编号:NCT04761601登记状态:提前终止企业 / 申办者:1200 Pharma, LLC
药物 / 成分:UCT-01-097、Gemcitabine、Paclitaxel
登记的停止原因(原文):Stopped for strategic business reasons. The decision to stop the study was not connected to any safety concerns, or new risk associated with the study product, intervention, or procedures.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study, Evaluating Efficacy and Safety of Allocetra-OTS in Patients With Severe or Critical COVID-19 With Associated Acute Respiratory Distress Syndrome (ARDS)
编号:NCT04922957登记状态:提前终止企业 / 申办者:Enlivex Therapeutics Ltd.
药物 / 成分:ALLOCETRA-OTS、Placebo
登记的停止原因(原文):strategic reprioritization
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
ARNI Versus plAcebo in Patients With Congenital sYStemic Right Ventricle Heart Failure
编号:NCT05117736登记状态:提前终止企业 / 申办者:Montreal Heart Institute
药物 / 成分:Sacubitril / Valsartan Oral Tablet、Placebo
登记的停止原因(原文):The trial was prematurely terminated due to safety concerns.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-03-13
A Phase II Study of Envofolimab and BD0801 With/Without Chemotherapy in Patients With Advanced Solid Tumors
编号:NCT05148195登记状态:提前终止企业 / 申办者:Jiangsu Simcere Pharmaceutical Co., Ltd.
药物 / 成分:Envofolimab、BD0801、Docetaxel、Irinotecan
登记的停止原因(原文):The study was terminated due to the sponsor's research and development strategy adjustment.
查看官方原始记录 ↗